Omega Diagnostics Investors - ODX

Omega Diagnostics Investors - ODX

[ADVERT]
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Omega Diagnostics Group Plc ODX London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-1.50 -5.66% 25.00 15:58:44
Open Price Low Price High Price Close Price Previous Close
26.25 24.25 26.75 25.00 26.50
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Top Investor Posts

DateSubject
01/12/2021
07:29
kirk 6: "...with manufacturing capacity on hand the company remains poised to pick up where it left off if the DHSC has a change of heart. In the fast changing environment triggered by Omicron that could happen. At such a low price, therefore, investors might want to keep a close eye on developments at Omega..."?????
01/12/2021
06:24
burtond1: Is it really game over for Omega Diagnostics ?"...with manufacturing capacity on hand the company remains poised to pick up where it left off if the DHSC has a change of heart. In the fast changing environment triggered by Omicron that could happen. At such a low price, therefore, investors might want to keep a close eye on developments at Omega..."https://total-market-solutions.com/2021/12/omega-diagnostics-group-plc/
29/11/2021
08:30
idiotsinthedarkrizandlintard: You guys are A+ investors and ClassA bankrupts 👏👏👏👏 8079;👏Ԁ79;👏👏;👏
28/11/2021
22:25
nxc: I have been reflecting on the potential for upside from the current price ( which I believe is underpinned by the other two divisions). 1. DHSC - much has been written about this and the Company found itself in an impossible position having been in active dialogue with DHSC until very recently. I guess it had a choice as to alienate DHSC or wrap some wording around the contract expiring and leaving the door open for further dialogue both with regard to the use of the equipment and/or supplying the preferred DHSC test. The Company has been accused of misleading investors re DHSC and whilst I feel badly let down I suspect that there was a genuine belief right up until Mid-November that they were going to secure a meaningful bit of business from DHSC.Will the opportunity ever return ? One would like to think given the many extra miles walked by the Company on behalf of this Government that there would be some recognition of this. However right at this moment in time it is impossible to forecast and any attempt to put any positive spin on the situation would be met with howls of derision. The Company though does need to go on the front foot without alienating DHSC and more actively engage with those that can rightly influence those in power.We have a good offering a good story to tell. I think the DHSC angle is far from dead but meaningful revenues will not be seen until second half of 2022. 2. HUA - I am confident that HUA will be forthcoming and that will provide a significant boost to revenues with commercial discussions awaiting final regulatory approval. 3. FDA - I personally do not see this happening in short order and even if it does happen the main action is in self-test and not professional testing. The scale of investment for the former is in my view beyond ODX's reach as it does not have the capital resources necessary to exploit the opportunity. I am left with the impression that the Company is as shell-shocked as we are by the decision of DHSC not to award any business currently to ODX ( do not get tied up with the legalese as that is just a convenient smokescreen) however all is not dead and I would like to think our country ultimately needs ODX and other UK diagnostic companies if it is to get out of this mess.
25/11/2021
21:44
nxc: Neo The buck ultimately stops with the Chairman and given the message that had to be delivered it would have taken some of the pressure off the Executive and I think given the Investors a fresh and perhaps more objective insight. I would agree there were errors of judgement on my watch and I have never shirked my responsibility in that regard. You are way off beam in implying a lack of integrity in my communication to Shareholders during my tenure - over optimism with hindsight yes telling fibbers no. I am clearly not to your taste but like you I have a right to express an opinion and I try to do that in a balanced way.
25/11/2021
18:35
specials_ bankruptcy_lawyer: I told u mugs last week we going to see 30p but u fools don’t listen and end up Filtering the genuine investors
23/11/2021
16:13
barrywhit: JJJ, A lot will sell out before results and you can't blame them as there has been NO encouragement from the company to hold on to your shares, dreadful Investor Relations..
08/11/2021
23:17
upomega: What about high net worth investors.???
18/8/2021
15:22
boxer_1: Andy first of all I held over 70,000 shares in ODX which I sold the lot now,and secondly I’m within my right to have a go at the ODX management for misleading investors stealing their hard earned money by ramping on Twitter. I made a decent profit here but i feel sorry for those who are down massively, I’m not a financial advisor and never advised anyone to buy/sell. ODX , have an obligation to answer the mounting investor concerns ,the management work for the investors , they have failed on all levels to be professional in communication,accountable and strategic decisions, the only people making money are the BOD.
13/4/2021
06:23
dafad: avacta have an investor presentation on the 22nd April,lets hope ther is news before then Notice of Results and Investor Presentation AVACTA GROUP PLC Released 07:00:05 13 April 2021 RNS Number : 2088V Avacta Group PLC 13 April 2021 13 April 2021 Avacta Group plc ("Avacta" or "the Group") Notice of Results and Investor Presentation Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, will announce its financial results for the 12 months ended 31 December 2020 on Thursday, 22 April 2021. Analyst briefing A sell-side analyst briefing given by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will be held by webcast presentation, followed by a Q&A session, at 9.30am BST on Thursday, 22 April 2021. Pre-registration is required for attendance to the call. To confirm attendance, please email Avacta@fticonsulting.com and you will be sent the link to join. The presentation will be posted on the Company's website at the following address: hxxps://avacta.com/investors/documents-presentations Investor webinar An investor webinar presentation by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will take place at 11:00am BST on Thursday, 22 April 2021. The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar: hxxps://www.investormeetcompany.com/avacta-group-plc/register-investor Investors who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited. - Ends -
ADVFN Advertorial
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211206 20:41:16